Cytoplasmic and nuclear HER4 expression in HER2 negative breast cancer cell lines

QR Code

Cytoplasmic and nuclear HER4 expression in HER2 negative breast cancer cell lines

HER4 cleavage and its subcellular localisations have been previously proven to mediate anti-HER2 resistance. The description of the HER4 subcellular localisations in HER2 negative breast cancer, on the other hand, is incomplete. The objective of this study was to determine the cytoplasmic and nuclea...

Full description

Bibliographic Details
Main Authors:	Siti Norasikin Mohd Nafi, Nursyazana Aqilah Ali
Format:	Article
Language:	English
Published:	Penerbit Universiti Kebangsaan Malaysia 2022
Online Access:	http://journalarticle.ukm.my/19170/ http://journalarticle.ukm.my/19170/1/19.pdf

Similar Items

Expression of HER4 isoforms and HER4 localisation in HER2 negative breast cancer cell lines
by: Ali, Nursyazana Aqilah
Published: (2021)

Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer
by: Drahman, Rosmaizan
Published: (2022)

BCL-2, HER1, HER2, HER3 and HER4 expression in primary colorectal adenocarcinoma
by: Ahmad Zubir, Nurul Mahirah
Published: (2017)

Computational pathology and deciphering the complexity of HER2 expression in breast cancer
by: Atallah, Nehal Mohammed
Published: (2025)

Translational control of Human Epidermal Growth Factor Receptors, HER2 and HER4 in response to cellular stresses in breast cancer cells
by: Edwards, Arnelle
Published: (2023)

The role of HER family signalling in breast cancer
by: Kuruppu, Anchala
Published: (2016)

Biological characterisation of HER2 amplified breast cancer
by: Barros, Fabrício Félix Tabuada
Published: (2013)

Adjuvant trastuzumab in HER2-positive breast cancer.
by: Slamon, D., et al.
Published: (2011)

HER2 positive metastatic breast cancer: What happens after first line failure?
by: Chan, Arlene
Published: (2016)

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2013)

Bioactivity of black cumin oil on the senescence of HER-2-overexpressing breast cancer cells
by: Faradiba Nur Ahlina,, et al.
Published: (2022)

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
by: Serra, V., et al.
Published: (2011)

Her2 challenge contest: a detailed assessment of automated her2 scoring algorithms in whole slide images of breast cancer tissues
by: Qaiser, Talha, et al.
Published: (2018)

Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness
by: Chan, Arlene
Published: (2016)

Expression of foxp3 tumour infiltrating lymphocytes in her2 positive breast cancer and their association with clinicopathological features
by: Hashim, Sobry
Published: (2023)

Her beauty & her terror : portrait of an archetypal land
by: Frantom, Michelle
Published: (2014)

It's her platform
by: Lim, Teik Huat
Published: (2018)

Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply
by: Chan, Arlene, et al.
Published: (2016)

Development of sandwich and label-free electrochemical immunosensor for detection of HER2 breast cancer biomarker
by: Lah, Zur Mira Azizah @ Nor Haiza
Published: (2018)

Her ideal platform
by: Lim, Teik Huat
Published: (2018)

Inhibition of HER2 enriches for Jagged1-dependent breast cancer stem cells: role for membrane Jagged1
by: Shah, Deep, et al.
Published: (2018)

HerMES: Far infrared properties of known AGN in the HerMES fields
by: Hatziminaoglou, E., et al.
Published: (2010)

Cytoplasmic cyclin E predicts recurrence in patients with breast cancer
by: Hunt, Kelly K., et al.
Published: (2016)

Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer
by: Cinieri, S., et al.
Published: (2017)

Virginia Woolf and her doctors
by: Trombley, Stephen
Published: (1980)

The Ground Beneath Her Feet
by: Khoo, Olivia
Published: (2008)

Frenceay finds her strength
by: Y.P. , Sivam
Published: (2012)

Carryn stamps her mark
by: Ishak, Fadhli
Published: (2016)

Husniah bides her time
by: Singh, Devinder
Published: (2017)

Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule
by: Nishimura, Yuya, et al.
Published: (2011)

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
by: Baselga, J., et al.
Published: (2017)

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2013)

Biological significance of human epidermal growth factor receptor 2 (HER2) in breast cancer: effect of oestrogen receptor
by: Ahmad, Dena Akram Jerjees
Published: (2016)

A woman in her own write
by: Abdul Manaf, Nor Faridah
Published: (1997)

HerMES: The SPIRE confusion limit
by: Nguyen, H., et al.
Published: (2010)

Giving asia her educational due
by: Joseph, Samatha
Published: (2012)

Comparison of tumour biomarker HER-2/neu (C-erbB-2) before and after surgery in breast cancer patients
by: Aung, Sanda, et al.
Published: (2014)

Osteoclast-specific marker nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 expression in stage III giant cell tumor of the bone
by: Jusoh, Mohd Hanifah
Published: (2018)

Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab
by: Chan, Arlene, et al.
Published: (2012)

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2014)